The FDA has granted approval to a second biosimilar to infliximab (Remicade, Johnson & Johnson). Infliximab-abda (Renflexis), an intravenous infusion developed by Samsung Bioepsis/Merck, has been approved for multiple indications.
This tumor necrosis factor (TNF) inhibitor has been indicated for various inflammatory conditions, including Crohn’s disease (adult and pediatric), ulcerative colitis, rheumatoid arthritis (combined with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
"Once Renflexis hits the market, it will be the first time we will see competition between 2 biosimilars, Inflectra and Renflexis, along with the reference product Remicade," said Brian Lehman, MBA, MHA, RPh, who is a manager of pharmacy benefits and policy in Columbus, Ohio. Lehman, who also serves on the editorial board of The Center for Biosimilars, added that Renflexis offers another important option for patients and providers in the treatment of serious inflammatory diseases.
The most common adverse reactions for infliximab-abda include infections, infusion-related reactions, headache, and abdominal pain, and its use is contraindicated with anakinra or abatacept. The label also indicates that the drug has not been evaluated in children under 6 years diagnosed with ulcerative colitis or Crohn’s disease.
Infliximab-abda will be available in single-dose vials containing 100 mg of lyophilized drug for a final reconstitution volume of 10 mL.
The first biosimilar to infliximab, infliximab-dyyb (Inflectra, Pfizer), was approved in November 2016. While Pfizer struggled for a while falling the launch of the drug, the company’s biosimilar revenues grew by 48% a year later—fourth quarter sales from Inflectra touched $61 million in 2016 (up from $30 million a year ago) despite the fact that the drug is being sold at only a 15% discount to Remicade.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.